Diary - News All news Alizé Pharma 3 : data from its AZP-3404 program in syndromes of severe insulin resistance

Alizé Pharma 3 : data from its AZP-3404 program in syndromes of severe insulin resistance

AZP-3404, an optimized peptide derived from IGFBP-2, improves glucose control in a preclinical model of severe insulin resistance through a new and unique mechanism of action

Lyon, France, March 21, 2019 - Alizé Pharma 3, a transatlantic company specialized in developing therapeutic peptides for the treatment of rare endocrine and metabolic diseases, today announces it will present preclinical results from its AZP-3404 program in syndromes of severe insulin resistance during the Annual Meeting of the Endocrine Society in New Orleans on March 23-26, 2019.